Revising the model for vaccine development: a step towards tuberculosis immunity
Barre latérale de l'article
Publié-e :
août 26, 2021
Mots-clés :
Tuberculosis, COVID-19, vaccines
Contenu principal de l'article
Renseignements sur l'article
Rubrique
Commentary
- Les auteurs qui publient dans le JMUO gardent les droits d’auteur de leurs articles, incluant tous les brouillons et la copie finale publiée dans le journal
- Bien que le JMUO n’a pas les droits d’auteur des articles soumis, en acceptant de publier dans le JMUO, les auteurs donnent le droit au journal d’être les premiers à publier et à distribuer leurs articles.
- Par la suite, les auteurs peuvent soumettre leurs documents à d’autres publications, incluant des revues ou des livres, avec un remerciement de leur première publication dans le JMUO
- Des copies du JMUO seront distribuées à la fois sous format papier et en ligne, et tous les matériaux seront accessibles au public en ligne. Le journal n’a pas de responsabilité légale par rapport à la distribution publique du contenu.
- Prière de vous assurer que tous les auteurs, les coauteurs et les investigateurs
- Le contenu est rendu disponible sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
Références
1. Government of Canada. Pfizer-BioNTech COVID-19 Vaccine (tozinameran) [Internet]. Government of Canada; [updated 2021 Mar 26; cited 2021 Mar 26]. Available from: https://covid-vaccine.canada.ca/pfizer-biontech-covid-19-vaccine/product-details
2. World Health Organization. Global tuberculosis report 2020. Geneva (CH): WHO Press; 2020. 232 p. Licence: CC BY-NC-SA 3.0 IGO.
3. Vachon J, Gallant V, Siu W. Tuberculosis in Canada, 2016. CCDR. 2018 Mar 1;44(3/4):75–81.
4. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. WHO Press; 2009. 314 p. ISBN 978 92 4 156380 2
5. Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 2020 Mar;13(2):190–204.
6. World Health Organization. Lack of new antibiotics threatens global efforts to contain drug-resistant infections [Internet]. World Health Organization; 2020 Jan 17 [cited 2021 Mar 26]. Available from: https://www.who.int/news/item/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections#:~:text=Declining%20private%20investment%20and%20lack,weak%20pipeline%20for%20antibiotic%20agents
7. Public Health Agency of Canada. Canadian Tuberculosis Standards 7th Edition. Ontario (CA): Government of Canada; 2014. Chapter 16: Bacille Calmette-Guérin (BCG) vaccination in Canada; p. 405.
8. Martin C, Aguilo N, Marinova D, Gonzalo-Asensio J. Update on TB Vaccine Pipeline. Applied Sciences. 2020 Apr 10;10(7):2632.
9. Kovesi T. Respiratory disease in Canadian First Nations and Inuit children. Paediatr Child Health. 2012 Aug 1;17(7):376-380.
10. Patterson M, Flinn S, Barker K. Addressing tuberculosis among Inuit in Canada. CCDR. 2018 Mar 1;44(3/4):82–5.
11. World Health Organization. Coronavirus update 45: Update on COVID-19 vaccine development [Internet]. World Health Organization; [updated 2020 Dec 21; cited 2021 Mar 26]. Available from: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update45-vaccines-developement.pdf?sfvrsn=13098bfc_5
12. Government of Canada. Backgrounder – Government of Canada investments in COVID-19 vaccines, therapeutics and biomanufacturing capacity [Internet]. Government of Canada; 2021 Feb 2 [cited 2021 Mar 26]. Available from: https://www.canada.ca/en/innovation-science-economic-development/news/2021/02/backgrounder--government-of-canada-investments-in-covid-19-vaccines-and-biomanufacturing-capacity.html
13. Treatment Action Group. Tuberculosis research funding trends 2005-2019. New York (US); 2020. 62 p.
14. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.
15. Li H, Liu L, Zhang W, Zhang X, Zheng J, Li L, et al. Analysis of the antigenic properties of membrane proteins of Mycobacterium tuberculosis. Sci Rep. 2019 Dec;9(1):3042.
2. World Health Organization. Global tuberculosis report 2020. Geneva (CH): WHO Press; 2020. 232 p. Licence: CC BY-NC-SA 3.0 IGO.
3. Vachon J, Gallant V, Siu W. Tuberculosis in Canada, 2016. CCDR. 2018 Mar 1;44(3/4):75–81.
4. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. WHO Press; 2009. 314 p. ISBN 978 92 4 156380 2
5. Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 2020 Mar;13(2):190–204.
6. World Health Organization. Lack of new antibiotics threatens global efforts to contain drug-resistant infections [Internet]. World Health Organization; 2020 Jan 17 [cited 2021 Mar 26]. Available from: https://www.who.int/news/item/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections#:~:text=Declining%20private%20investment%20and%20lack,weak%20pipeline%20for%20antibiotic%20agents
7. Public Health Agency of Canada. Canadian Tuberculosis Standards 7th Edition. Ontario (CA): Government of Canada; 2014. Chapter 16: Bacille Calmette-Guérin (BCG) vaccination in Canada; p. 405.
8. Martin C, Aguilo N, Marinova D, Gonzalo-Asensio J. Update on TB Vaccine Pipeline. Applied Sciences. 2020 Apr 10;10(7):2632.
9. Kovesi T. Respiratory disease in Canadian First Nations and Inuit children. Paediatr Child Health. 2012 Aug 1;17(7):376-380.
10. Patterson M, Flinn S, Barker K. Addressing tuberculosis among Inuit in Canada. CCDR. 2018 Mar 1;44(3/4):82–5.
11. World Health Organization. Coronavirus update 45: Update on COVID-19 vaccine development [Internet]. World Health Organization; [updated 2020 Dec 21; cited 2021 Mar 26]. Available from: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update45-vaccines-developement.pdf?sfvrsn=13098bfc_5
12. Government of Canada. Backgrounder – Government of Canada investments in COVID-19 vaccines, therapeutics and biomanufacturing capacity [Internet]. Government of Canada; 2021 Feb 2 [cited 2021 Mar 26]. Available from: https://www.canada.ca/en/innovation-science-economic-development/news/2021/02/backgrounder--government-of-canada-investments-in-covid-19-vaccines-and-biomanufacturing-capacity.html
13. Treatment Action Group. Tuberculosis research funding trends 2005-2019. New York (US); 2020. 62 p.
14. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.
15. Li H, Liu L, Zhang W, Zhang X, Zheng J, Li L, et al. Analysis of the antigenic properties of membrane proteins of Mycobacterium tuberculosis. Sci Rep. 2019 Dec;9(1):3042.